Association of nevirapine levels with rash or hepatotoxicity among HIV-infected Thai women

Open AIDS Journal

Volumn 6, Issue 1, 2012, Pages 266-273

  Ratanasuwan, Winai ^a   Jariyasethpong, Tavatchai ^b   Anekthananon, Thanomsak ^a   Intalapaporn, Poj ^b   Kongpatanakul, Supornchai ^c   Pongnarin, Piyapat ^c   Wasinrapee, Punneeporn ^d   Chantharojwong, Nartlada ^d   Raengsakulrach, Boonyos ^d   Peters, Philip J ^e   Mcnicholl, Janet ^e   Mcconnell, Michelle S ^d,e   Weidle, Paul J ^e  

^a MAHIDOL UNIVERSITY   (Thailand)

^b RAJAVITHI HOSPITAL   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d Centers for Disease Control CDC Thailand Field Station   (Thailand)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Adverse effect; Antiretroviral; Hepatotoxicity; Nevirapine; Rash; Thailand

Indexed keywords

FLUCONAZOLE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; STAVUDINE;

ADULT; ARTICLE; BODY MASS; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; LIVER TOXICITY; MAJOR CLINICAL STUDY; MORNING DOSAGE; PREDICTIVE VALUE; PRIORITY JOURNAL; RASH; SENSITIVITY AND SPECIFICITY; THAILAND; VIRUS LOAD;

EID: 84885335236     PISSN: None     EISSN: 18746136     Source Type: Journal    
DOI: 10.2174/1874613601206010266     Document Type: Article

References (31)

1. Ananworanich J, Moor Z, Siangphoe U, et al. Incidence and risk factorsfor rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS 2005; 19: 185-92.
2. Zhou J, Phanupak P, Kiertiburanakul S, Ditangco R, Kamarulzaman A, Pujary S. Highly active antiretroviral treatment containing efavirenz or nevirapine and related toxicity in the TREAT Asia HIV Observational Database. J Acquir Immune Defic Syndr 2006; 43: 501-3.
3. Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, anonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 1998; 20: 1071-92.
4. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine:safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995; 171: 537-45.
5. Cheeseman SH, Hattox SE, McLaughlin MM, et al. Pharmacokineticsof nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother 1993; 37: 178-82.
6. la Porte CJL, Back DB, Blaschke T, et al. Updated guideline to performtherapeutic drug monitoring for antiretroviral agents. Rev Antivir Ther 2006; 3: 4-14.
7. de Maat MM, Ter Heine R, Mulder JW, et al. Incidence and risk factorsfor nevirapine-associated rash. Eur J Clin Pharmacol 2003; 59: 457-62.
8. De Requena DG, Jimenez-Nacher I, Soriano V. Changes in nevirapineplasma concentrations over time and its relationship with liver enzyme elevations. AIDS Res Hum Retroviruses 2005; 21: 555-9.
9. Almond LM, Boffito M, Hoggard PG, et al. The relationship betweennevirapine plasma concentrations and abnormal liver function tests. AIDS Res Hum Retroviruses 2004; 20: 716-22.
10. Kappelhoff BS, van Leth F, MacGregor TR, Lange J, Beijnen JH, Huitema AD. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther 2005; 10: 145-55.
11. Kappelhoff BS, van Leth F, Robinson PA, et al. Are adverse events ofnevirapine and efavirenz related to plasma concentrations? Antivir Ther 2005; 10: 489-98.
12. Autar RS, Wit FW, Sankote J, et al. Nevirapine plasma concentrationsand concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antivir Ther 2005; 10: 937-43.
13. Stringer JSA, McConnell MS, Kiarie J, et al. Effectiveness of Non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study. PLoS Med 2010; 7: 1-13.
14. Peters PJ, Stringer JSA, McConnell MS, et al. Nevirapine-associatedhepatotoxicity was not predicted by CD4 cell count ≥ 250 cells/μL among women in Zambia, Thailand, and Kenya. HIV Med 2010; 11: 650-60.
15. NIH Division of AIDS. Division of AIDS table for grading the severityof adult and pediatric adverse events. 2004. Available at: http://www3.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/PDF/DAIDSAEGradingTable.pdf. [Last Updated: December 2004, Accessed: 5 November 2009]
16. Zerit [package insert]. Princeton NJ: Bristol-Myers Squibb; 2009.
17. Epivir [package insert]. Research Triangle Park, NC: Glaxo SmithKline 2009.
18. Lea AP, Faulds D. Stavudine: a review of its pharmacodynamic andpharmacokinetic roperties and clinical potential in HIV infection. Drugs 1996; 51: 846-64.
19. vanPraag RME, van Weert ECM, van Heeswijk RPG, et al. Stableconcentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy. Antimicrob Agents Chemother 2002; 46: 896-9.
20. Horton CM, Dudley MN, Kaul S, et al. Population pharmacokinetics ofstavudine (d4T) in patients with AIDS or advanced AIDS-related complex. Antimicrob Agents Chemother 1995; 39: 2309-15.
21. Rana KZ, Dudley MN. Clinical pharmacokinetics of stavudine. ClinPharmacokin 1997; 33: 276-84.
22. Yuen GJ, Lou Y, Bumgarner NF, et al. Equivalent steady-statepharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother 2004; 48: 176-82.
23. Bruno R, Regazzi MB, Ciappina V, et al. Comparison of the plasmapharmacokinetics of lamivudine during twice and once daily administration in patients with HIV. Clin Pharmacokin 2001; 40: 695-700.
24. Sabo JP, Lamson MJ, Gerhard L, Yong CL, Mac Gregro TR.Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection. AAPS Pharm Sci 2002; 2: 1-7.
25. Viramune [package insert]. Ridgefield, CT: Boehringer-IngelheimPharmaceuticals Corp 2008.
26. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicityassociated with nevirapine use in HIV-infected subjects. J Infect Dis 2005; 191: 825-82.
27. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapineuse. J Acquir Immune Defic Syndr 2004; 35(5): 538-9.
28. Coffie PA, Tonwe-Gold B, Tanon AK, et al. Incidence and risk factorsof severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Cote d'Ivoire. BMC Infect Dis 2010; 10: 188.
29. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. Acomprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003; 34(Suppl 1): S21-33.
30. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35: 182-9.
31. Weidle PJ, Moore D, Mermin J, et al. Liver enzymes improve over 24months of first-line non-nucleoside reverse transcriptase inhibitor-based therapy in rural Uganda. AIDS Patient Care and STDs 2008; 22(10): 1-9.